Increased Expressions of IL-22 and Th22 cells in the coxsackievirus B3-Induced mice acute viral myocarditis
© Kong et al.; licensee BioMed Central Ltd. 2012
Received: 10 June 2012
Accepted: 30 September 2012
Published: 11 October 2012
Recently, a new subset of T helper (Th) cell that predominantly secret cytokine interleukin-22 (IL-22) is identified, termed Th22 cells. The Th22 subset has been demonstrated to be involved in immunity and tissue inflammation. However, the existence of Th22 cells and role of IL-22 in acute viral myocarditis (AVMC) remain unknown.
BALB/c mice were intraperitoneally (i.p) infected with CVB3 for establishing AVMC models. Control mice were treated with phosphate-buffered saline (PBS) i.p. On day 14 post injection, frequencies of splenic Th22 cells were determined, productions of IL-22 and expressions of IL-22R (IL-22 receptor) were measured. To further investigate the effects of IL-22, AVMC mice treated with Anti-IL-22 neutralizing antibody were explored. The severity of AVMC were monitored; the frequencies of Th22 cells, the expressions of IL-22 and IL-22R were investigated; in addition to IFN-γ, inflammatory cytokines IL-17, TNF-α, IL-6 as well as IL-1β, were evaluated. Cardiac viral replication were detected.
Compared with control group, significant elevations of circulating Th22 cells and IL-22, cardiac protein and mRNA of IL-22, and IL-22R1 were demonstrated in AVMC group. Treatment of AVMC mice with Anti-IL-22 Ab exacerbated the severity of viral myocarditis, verified by lower survival rate, higher HW/BW ratios and cardiac pathological scores. Anti-IL-22 Ab decreased the frequencies of Th22 cells and the levels of IL-22, and increased the expressions of cardiac IL-22R1. Up-regulations of IL-17, IL-6 and TNF-α, down-regulations of IFN-γ proteins and gene expressions in the plasma and myocardium, were observed in Anti-IL-22 Ab group. Furthermore, neutralization of IL-22 significantly promoted cardiac viral replication.
Our data indicate that the increased frequencies of IL-22-producing Th22 cells may play an important role in the pathogenesis of CVB3-induced mice AVMC, IL-22 may act as an myocardium-protective cytokine via the IL-22–IL-22R pathway, and suggest that targeting the Th22 cell and IL-22–IL-22R pathway could provide new therapeutic modalities for the treatment of CVB3-induced AVMC.
KeywordsTh22 cells IL-22–IL-22R pathway Acute viral myocarditis
Acute viral myocarditis (AVMC) is characterized by myocardial inflammation and can progress to chronic dilated cardiomyopathy (DCM), a terminal condition requiring transplantation. Coxsackievirus B (CVB), an enterovirus of the Picornaviridae family, its infection is surprisingly prevalent, with an estimated 70% of the human population having exposed to these viruses. CVB3, a member of the CVB group, is the primary pathogen of viral myocarditis . Accumulating data had indicated the dominant cause of myocardial cells damage in AVMC were inflammation and autoimmune responses triggered by the viral infection, mediated by T cells and their cytokines [1–3]. Emerging evidence have demonstrated that several Th subsets, such as Th1, Treg, Th17 but not Th9 cells, are involved in the pathogenesis of AVMC [4–8]. But the fundamental mechanisms responsible for AVMC are not completely clarified, and therapeutics for AVMC are restricted to supportive care including basic medications .
Recently, the Th22 cell has been recognized as a novel Th cell subset, which is characterized by abundant production of IL-22 but not IL-17 or IFN-γ [10–12]. This newly identified CD4+T cells clones have low or undetectable expression of transcription factor T-bet and RORγt (Th1 and Th17). With the CCR6+CCR4+CCR10+ phenotype, aryl hydrocarbon receptor (AHR) has been considered to be the key transcription factor of Th22 subset. Driven by the combined effects of IL-6 and TNF-a, naïve T cells differentiate toward the Th22 phenotype in human . All of above evidence strongly support that the Th22 cell represent a terminally differentiated and independent T cells subtype. Demonstrated by emerging literature in kinds of diseases such as rheumatoid arthritis, atopic dermatitis, systemic sclerosis, human immunodeficiency virus (HIV) infection, Th22 cells were considered providing a unique contribution to tissue inflammation, virus infection and immune responses [13–16].
IL-22, the crucial Th22 signature cytokine, its role had been demonstrated by developing literatures, which reported that neutralization or genetic deletion of IL-22 could alleviate or exacerbate the severity of kinds diseases such as antigen-induced airway inflammation and T cell-mediated hepatitis [17, 18], indicating that targeting IL-22 might represent a promising novel therapeutic approach for acute-phase response, immunity and inflammation. IL-22 mediates its effects via IL-22R, a heterodimeric transmembrane receptor complex consisting of IL-10R2 and tissue-specific IL-22R1 . IL-10R2 is ubiquitously expressed, while the expression of IL-22R1 is restricted to nonhematopoietic cells. Signaling through IL-22R1 is restricted to IL-22, and tissues that lack IL-22R1 will not be a target for IL-22 under currently known molecular pathways. An increasing number of human-and mouse-based studies have indicated that IL-22–IL-22R interactions can modulate the expressions of considerable genes such as IL-17,IFN-γ,IL-1β,TNF-α,IL-6, and highlighted the fact that IL-22–IL-22R interactions are an integral pathway through which cells of the innate and adaptive immune responses regulate immunity and inflammation [20–22].
The existence of Th22 cells in CVB3-induced mice AVMC is still unclear. The roles of both IL-22 and the IL-22–IL-22R pathway in the pathogenesis of AVMC remain to be clarified. Therefore, our present study examined the frequencies of Th22 cells, investigated the expressions of IL-22 and IL-22R, targeted of IL-22 in vivo in mice AVMC with the use of neutralizing Anti-IL-22 antibodies, and aimed to preliminary explore the presence of Th22 cells and functional characteristics of IL-22 in AVMC.
Evaluation for the severity of AVMC
Elevated expressions of IL-22 and IL-22R in AVMC
On day 14 post infection, compared with those in control mice treated with PBS only, much higher levels of the IL-22 protein and gene transcripts were detected in myocardium in AVMC mice, respectively (236.24 ± 43.26 vs. 17.45 ± 5.21, 21.28 ± 4.28 vs. 4.28 ± 0.97, both p<0.01, Figure 1B,C and E). As shown in Figure 1D, the significantly increased level of the circulating IL-22 protein in the AVMC group was observed compared with that in the control group (20.21 ± 3.81 vs. 3.02 ± 0.83pg/ml, p<0.01). Meanwhile, the relative cardiac gene expression of IL-22R1, the specific receptor of IL-22, was obviously up-regulated in the AVMC group, compared with that in the control group (3.01 ± 0.78 vs. 1.05 ± 0.29, p<0.01). In contrast, the relative cardiac transcripts of IL-10R2 in the AVMC group were less than those in the control group (43.28 ± 9.14 vs. 58.5 ± 9.01, p<0.05).
Increased proportions of Th22, Th17 and Th1 cells in AVMC
Neutralization of IL-22 exacerbated the severity of AVMC
Neutralization of IL-22 decreased the percentage of the Th22 cell and dysregulated the expressions of the IL-22–IL-22R pathway
Neutralization of IL-22 increased the productions of IL-17, TNF-α and IL-6, decreased the level of IFN-γ
Neutralization of IL-22 promoted viral replication
Compared with those in PBS and IgG control groups, the levels of cardiac CVB3 RNA and CVB3 titers in the Anti-IL-22 Ab group were elevated markedly, indicated by RT-PCR and plaque-forming unit (PFU) experiments (Figure 5F, all p<0.01). However, no obvious differences in these levels were observed between PBS and IgG control groups (p>0.05).
There is growing evidence that T cell activation and its cytokine expression play a key role in the pathogenesis of CVB3-induced AVMC, such as IFN-γ-producing Th1 cells and IL-17-producing Th17 cells [4–7]. Recently, several works related to Th22 cells have broadened our understanding of T cell-mediated tissue inflammation and immunity [13–16]. Pure Th22 cells represents a distinct CD4+T cell subset characterizing by the secretion of IL-22, but not IL-17 or IFN-γ, thus is identified as IL-22+IL-17-IFN-γ-CD4+T cells [10–12, 16]. IL-22, the crucial cytokine of Th22 cells, mediates its effects via IL-22R and propagates downstream signals including JAK/STAT, ERK, JNK, PI-3K and p38 MAP kinase pathways [19, 23, 24]. A considerable amount of data indicated that the Th22 cell and its crucial cytokine IL-22 could exert either pro-inflammatory or anti-inflammatory activities depending on the context [13–18, 22]. In the present work, we tried to exploit the potential that Th22 cells may participate in the inflammatory and immune response in AVMC. As excepted, higher percentage of the Th22 cell was observed in CVB3-induced mice AVMC, similarly to those of Th17 and Th1 cells. Our data uncovered the evidence of significant elevations in circulating Th22 cells and IL-22 proteins, cardiac mRNA and protein expressions of IL-22 in AVMC. It seems that infective and immunity microenvironment of AVMC is suitable for the differentiation and proliferation of Th22 cells. These novel findings confirm an individual signature for the IL-22-producing Th22 subset in AVMC, and provide a cellular target for therapeutic intervention and may also shed light on thus far unknown pathways in the control of AVMC.
Based on the observation that levels of IL-22 and IL-22 receptor were elevated in AVMC, we examined the efficacy of IL-22 in the AVMC mouse model, with the use of anti-IL-22 antibody (Anti-IL-22Ab) [20, 25]. Functional studies in human or murine model systems have indicated that IL-22 could be either pathologic or protective, depending on the context in which it was expressed [17, 18, 22, 26, 27]. Our results proved that neutralization of IL-22 exacerbated the severity of AVMC, which was verified by the lower survive rate, higher values of HW/BW and pathological scores of heart sections. Meanwhile, down-regulations of circulating Th22 cells and IL-22 were observed in the Anti-IL-22Ab group. The Th22 cell is not the unique source of IL-22. However, Both the pathogenic effect of Anti-IL-22 Ab in our AVMC model and protective role of the IL-22-Ig fusion gene in experimental autoimmune myocarditis (EAM) model , suggest that this cytokine has an important myocardium-protective role regardless of the cell source.
Emerging literature indicate that IL-22 participates in immunity and tissue inflammation through the IL-22–IL-22R pathway [20, 22]. To explore the role of this pathway in AVMC, we firstly investigated the expressions of cardiac IL-22 and IL-22R, the latter which consists of IL-22R1 and IL-10R2. Because signaling through IL-22R1 is restricted to IL-22, we focused on IL-22 and IL-22R1 . Compared with IL-22 and IL-22R1, dramatically higher relative cardiac expression of IL-10R2 was detected in mice, consistence with previous data that IL-10R2 was highly expressed [20, 22]. Compared with those in the control group, significant elevations of IL-22 and IL-22R1 were identified in the AVMC group. Although the major IL-22-producer are immune cells, it has been confirmed that IL-22R1 expression is absent on immune cells but instead restricted to tissues, thus IL-22 acts as a middle-men between the immune system and its environment . These increases of cardiac IL-22 and IL-22R1 may strengthen signaling directionality from the immune system to myocardium, and are thus involved with the pathogenesis of AVMC. After IL-22 was blockade with a neutralizing antibody in AVMC, down-regulations of IL-22 and up-regulations of IL-22R1 were observed. These data are consistent with a previous study that IL-22R1 expression was decreased after treatment with rIL-22 but increased after IL-22 neutralization, while IL-10R2 was not changed significantly in liver ischemia-reperfusion injury model, by RT-PCR analysis . These phenomena may be explained by the following mechanism: IL-22R1 has been recognized as a driver of inflammation, and has a autoregulatory feedback loop that amplifies the level of IL-22 [29, 30]. When IL-22 is decreased by neutralization of anti-IL-22 Ab, IL–22R1 may be increased by autoregulatory feedback loop that promotes the levels of IL-22. And the promotion of IL-22R1 further aggravates the myocarditis in the anti-IL-22 group. On the other hand, IL-10R2 is constitutively expressed on virtually all cells types at high levels and is an component of the receptor complexes for IL-22, IL-10, IL-26, IL-28, and IL-29, thus the effect of anti-IL-22 on the expression of IL-10R2 is not significant. Further investigation with the use of heart-specific IL-22 transgenic mice and mice that lack IL-22R1 will be of particular interest to clarify the dysregulation of the IL-22–IL-22R pathway in AVMC.
Our data suggest that dysregulated IL-22–IL-22R signal can modulate expressions of considerable genes and regulate the productions of inflammatory cytokines, verified by the fact that IL-22 neutralization significantly promoted the circulating and cardiac IL-17, IL-6, TNF-α, which have been identified as important pro-inflammatory cytokines and exacerbating myocarditis by inflammation and immunity [4, 5]. More specifically, dysregulated IL-22–IL-22R pathway in the Anti-IL-22 Ab group contributed to cardiac viral replication, and decreased the level of IFN-γ, which was considered as the vital defenders against viral infection [28, 31]. Our data was consistent with the previous observation that IL-22 contributed to resistance to viral infection , highlighting a role for IL-22-producing Th22 cells in controlling cardiac viral replication in AVMC. It seems whether IL-22 response modulates the expression of IL-1β is context dependent because no significant change of IL-1β production was observed in the Anti-IL-22 Ab group [20, 33, 34].
To our knowledge, this is the first demonstration that Th22 and IL-22–IL-22R pathway may participate in the development of AVMC but with several limitations. First, the neutralization of IL-22 antibody biological activity was not fully quantified, and we have not addressed the mechanism responsible for proliferation of Th22 cells in mice. Whether the decreased Th22 cells in the anti-IL-22Ab group was due to the ab neutralizing or impaired proliferation, required future study. Second, Th22 has been regarded as the most important IL-22-producing CD4+T cells (71.9%) , elucidation of the role of the IL-22–IL-22R pathway would be helpful to understand the whole picture of Th22 cells-involved in AVMC. However, the source of IL-22 was not limited by the Th22 cell. NKT,Th17, Tc17, innate-like γδT, even in Rag2−/− mice which lack of T cells, are IL-22 producers in mice [22, 35]. Thus the myocardium-protective role of IL-22 could not be used to absolutely identify the Th22 function. In future studies on transcription factor AHR, chemokine receptor CCR6, PI-3 kinase pathway based-screening, will be of benefit to understanding of the Th22 cell regulation during inflammatory responses in AVMC [23, 24]. Furthermore, whether RORC reflects the capacity to produce IL-17 and IL-22 in AVMC, is an interesting open issue.
In summary, our preliminary data demonstrate that enriched IL-22-producing Th22 cells represent a distinct T cell subset in CVB3-induced mice AVMC. IL-22 may play a myocardium-protective role through the IL-22–IL-22R pathway in AVMC. Further studies focusing on the differentiation, regulation, downstream pathways of IL-22-producing Th22 cells, especially in human systems, are required to comprehensively explore the therapeutic potential of Th22 cells in AVMC.
Specific pathogen-free male BALB/c mice aged 6 week were purchased from the Hunan Laboratory Animal Centre, Chinese Academy of Sciences, Hunan, China (Certificate No. SCXK (Xiang) 2009–0004). All animals were kept in the pathogen-free mouse room in the experimental animal center (Experimental Animal Center of the Guangxi Medical University, Nanning,China), and all experiments were carried out in accordance with protocols approved by Guangxi Medical University Animal Ethics Committee.
The CVB3 (Nancy strain, from Institute of immunology of Guangxi Medical University) was maintained by passage through Hep-2 cells. The virus titer determined by PFU assay was 1×108. The CVB3 was diluted in PBS (Solarbio Science & Technology Co, Ltd, Beijing, China). BALB/c mice were infected by an intraperitoneally injection (i.p) of 100 μl PBS containing approximately ∼106 PFUs of the virus for establishing AVMC models.
Induction of AVMC
A total of 32 mice were randomly divided into two groups: 1) in the AVMC group, BALB/c mice were treated with CVB3 (100 μl per mouse) i.p. (n = 20); 2) mice administered i.p. with PBS were taken as control (n = 12). The day when mice were injected i.p. was defined as day 0. All surviving animals were sacrificed on day 14 after infection. Hearts and spleens were removed aseptically as fresh specimens to be measured, blood was harvested and the plasma was prepared for study.
Neutralization of IL-22
For in vivo IL-22 neutralization, a total of 36 mice which infected with CVB3 (AVMC mice) were randomly divided into three groups: administered either Anti-IL-22 Ab (50 μg per mouse; R&D Systems, Inc. Minneapolis, MN.AF582; n=12,Anti-IL-22Ab group); an normal IgG control (50 μg per mouse; R&D Systems,Inc. Minneapolis,MN.AB-108-C; n=12, IgG control group); or PBS (n=12, 50 μg per mouse; PBS group) i.p., at day 0. All surviving animals were sacrificed on day 14 after CVB3 infection. The survival rates and values of the heart weight/body weight (HW/BW) were recorded. The hearts, spleens and plasma were collected.
The ventricular tissues of the hearts were fixed in 10% formalin, then embedded in paraffin. After sectioned along the entire length of the heart into 5-μm sections, and stained with H&E (hematoxylin and eosin), histopathological change was observed by using light microscopy (Nikon Eclipse E800 Microscope, Kawasaki, Kanagawa, Japan). Pathological scores were graded by two independent pathologists separately in a blinded manner based on the following semi-quantitative scale: 0, no inflammatory infiltrates; 1, small foci of inflammatory cells between myocytes or inflammatory cells surrounding individual myocytes; 2, larger foci of 100 inflammatory cells or involving at least 30 myocytes; 3, 10% of a myocardial cross-section involved; 4, 30% of a myocardial cross-section involved .
Spleens from mice were collected aseptically. After mincing, splenic cells were gently dispersed through nylon mesh into a single-cell suspension. Then these splenic mononuclear cell suspension was washed with RPMI 1640 (Gibco, USA). The lymphocyte fractions of these samples were obtained by Ficoll-Plaque (Solarbio Science & Technology, China) gradient centrifugation. Then cells were resuspended in RPMI 1640 medium with 10% FCS (Gibco, USA), stimulated with phorbol myristate acetate (PMA, 25ng/ml, Sigma- Aldrich, USA) and ionomycin (1μg/ml, Sigma-Aldrich) in the presence of GolgiPlug(1 ul/106cells, BD Biosciences) at 37°C, 5% CO2 of a 24-well culture plate. After 4h incubation, the cells were harvested and stained with phycoerythrin Cye-5- conjugated anti-mouse CD4 (PE-Cye-CD4, BD Biosciences). Then cells were stained intracellularly with anti–IL-22, –IL-17, or –IFN-γ mAb conjugated with APC, PE, or AF488(Alexa-Fluor®488)after fixation and permeabilization (BD Biosciences, eBioscience), analyzed on a FACS-Calibur flow cytometer (BD Bioscience). Cell Quest soft-ware (BD Biosciences) was used for data acquisition. Pure Th22 cells were defined as IL-22+IL-17-IFN-γ-CD4+.
Immunohistochemical staining was performed by the streptavidin-biotin complex method according to the manufacturer’s instructions. Rabbit polyclonal antibodies against mouse IL-22 (Abcam, USA) at a 1:200 dilution were used as primary antibodies. The sections were washed and stained using the streptavidin-biotin complex kit (Boster, Wuhan, China). After the sections were rehydrated, endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10 min at room temperature. Then the sections were first incubated in 5% bovine serum albumin for 20 min and then in the primary antibody for 24h at 4°C, and incubated with the streptavidin-biotin complex for 20 min. At last, the sections were developed with 3,3-diaminobenzidine (Boster, Wuhan, China) and observed under a light microscope. Instead of primary antibody, non-immune goat serum was taken as a control. IL-22 deposition in the cytoplasm and cytomembrane of myocardium were evaluated semi-quantitatively according to the extent and intensity of staining using Image-Pro Plus Version 6.0 (Media Cybernetics, Bethesda, MD). 5 fields from each slice were randomly selected by two pathology experts, who were unaware of the groups and evaluated by integrated optical density (IOD).
Viral titers were determined by standard plaque formation assay. After part of the heart was weighed and homogenized in 2 ml PBS, three freeze-thaw cycles and centrifuging at 2000 rpm for 10 min were undertaken, then supernatant was sequential 10-diluted in RPMI 1640 medium. The HeLa cell monolayers were incubated with the supernatant for 1 h at 37°C, 5% CO2, in six-well plates, washed in PBS, and covered with 2 ml 0.4%agar, DMEM, and 5%FCS. After 72 h of cultivation, the monolayers were fixed in para formaldehyde and stained in crystal violet, and the numbers of plaques were counted. Viral titers were expressed per organ weight (in grams).
Sequences of primers for real-time RT-PCR
Cytokine content was determined by enzyme-linked immunosorbent assays on plasma. The amounts of IL-22 were detected using the Quantikine Mouse IL-22 Immunoassay (Biolegend,Cat.No.436307,USA). The levels of IL-17A,IFN-γ, IL-1β,TNF-α,IL-6 in mice were determined by ELISA kits (Shanghai ExCell Biology Inc. China), according to the manufacturer’s instructions. The sensitivity of ELISA kits for IL-22,IL-17,IFN-γ,IL-1β,TNF-α,IL-6 was 5,7,7,7,4 and 7pg/ml, respectively, and no cross-reactivity was observed in detection. All samples were measured in triplicate.
Statistical analyses of data were performed with one-way ANOVA. Correlations were determined by Spearman rank correlation coefficients. Survival was estimated by the Kaplan-Meier method and compared by the log-rank test. The differences between pathological scores were evaluated using the Mann–Whitney U test. All data were analyzed with SPSS 17.0. Differences were deemed to be statistically significant at p<0.05.
Acute viral myocarditis
Human immunodeficiency virus
Real time-polymerase chain reaction
Enzyme linked immosorbent assay
This work is supported by the grants from the National Natural Science Foundation of China (No.30960129; 81260045). We thank Dr. Lan Jiao, Liang Zoujiu,Huang Qiguang for technical assistances.
- Crocker SJ, Frausto RF, Whitmire JK, Benning N, Milner R, Whitton JL: Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1. Am J Pathol. 2007, 171 (6): 1762-1773. 10.2353/ajpath.2007.070179.PubMedPubMed CentralView ArticleGoogle Scholar
- Liu PP, Mason JW: Advances in the understanding of myocarditis. Circulation. 2001, 104 (9): 1076-1082. 10.1161/hc3401.095198.PubMedView ArticleGoogle Scholar
- Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, Sonderegger I, Bachmaier K, Kopf M, Penninger JM: Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med. 2003, 9 (12): 1484-1490. 10.1038/nm960.PubMedView ArticleGoogle Scholar
- Fan Y, Weifeng W, Yuluan Y, Qing K, Yu P, Yanlan H: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus B3-Induced viral myocarditis reduces myocardium inflammation. Virol J. 2011, 8: 17-10.1186/1743-422X-8-17.PubMedPubMed CentralView ArticleGoogle Scholar
- Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, Wang JP, Zhang JH, Wang M, Guo HP, Cheng X, Liao YH: Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol. 2010, 185: 4004-4010. 10.4049/jimmunol.1001718.PubMedView ArticleGoogle Scholar
- Xie Y, Chen R, Zhang X, Chen P, Liu X, Xie Y, Yu Y, Yang Y, Zou Y, Ge J, Chen H: The role of Th17 cells and regulatory T cells in Coxsackievirus B3-induced myocarditis. Virology. 2011, 421 (1): 78-84. 10.1016/j.virol.2011.09.006.PubMedView ArticleGoogle Scholar
- Qing K, Weifeng W, Fan Y, Yuluan Y, Yu P, Yanlan H: Distinct different expression of Th17 and Th9 cells in coxsackie virus B3-induced mice viral myocarditis. Virol J. 2011, 8: 267-10.1186/1743-422X-8-267.PubMedPubMed CentralView ArticleGoogle Scholar
- Fairweather D, Rose NR: Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods. 2007, 41: 118-122. 10.1016/j.ymeth.2006.07.009.PubMedPubMed CentralView ArticleGoogle Scholar
- Liu Z, Yuan J, Yanagawa B, Qiu D, McManus BM, Yang D: Coxsackievirus-induced myocarditis: new trends in treatment. Expert Rev Anti Infect Ther. 2005, 3: 641-650. 10.1586/1478722.214.171.1241.PubMedView ArticleGoogle Scholar
- Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F: Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009, 10: 857-863. 10.1038/ni.1767.PubMedView ArticleGoogle Scholar
- Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, Cavani A: Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009, 119 (12): 3573-3585.PubMedPubMed CentralGoogle Scholar
- Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H: Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009, 10: 864-887. 10.1038/ni.1770.PubMedView ArticleGoogle Scholar
- Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, Hu NW, Ma DX, Li ZF, Yang Q, Li W, Li JM: Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012, 7 (4): e31000-10.1371/journal.pone.0031000.PubMedPubMed CentralView ArticleGoogle Scholar
- Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, Ramon M, Bergman R, Krueger JG, Guttman-Yassky E: IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009, 123 (6): 1244-1252. 10.1016/j.jaci.2009.03.041. e2PubMedPubMed CentralView ArticleGoogle Scholar
- Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C: Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther. 2011, 13 (5): R166-10.1186/ar3486.PubMedPubMed CentralView ArticleGoogle Scholar
- Kim CJ, Nazli A, Rojas OL, Chege D, Alidina Z, Huibner S, Mujib S, Benko E, Kovacs C, Shin LY, Grin A, Kandel G, Loutfy M, Ostrowski M, Gommerman JL, Kaushic C, Kaul R: A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. Mucosal Immunol. 2012, in pressGoogle Scholar
- Takahashi K, Hirose K, Kawashima S, Niwa Y, Wakashin H, Iwata A, Tokoyoda K, Renauld JC, Iwamoto I, Nakayama T, Nakajima H: IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation. J Allergy Clin Immunol. 2011, 128 (5): 1067-1076. 10.1016/j.jaci.2011.06.018. e1-6PubMedView ArticleGoogle Scholar
- Radaeva S, Sun R, Pan HN, Hong F, Gao B: Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology. 2004, 39 (5): 1332-1342. 10.1002/hep.20184.PubMedView ArticleGoogle Scholar
- Wolk K, Witte E, Witte K, Warszawska K, Sabat R: Biology of interleukin-22. Semin Immunopathol. 2010, 32 (1): 17-31. 10.1007/s00281-009-0188-x.PubMedView ArticleGoogle Scholar
- Chestovich PJ, Uchida Y, Chang W, Ajalat M, Lassman C, Sabat R, Busuttil RW, Kupiec-Weglinski JW: Interleukin-22: implications for liver ischemia-reperfusion injury. Transplantation. 2012, 93 (5): 485-492. 10.1097/TP.0b013e3182449136.PubMedPubMed CentralView ArticleGoogle Scholar
- Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ, Ouyang W: Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008, 14 (3): 282-289. 10.1038/nm1720.PubMedView ArticleGoogle Scholar
- Sonnenberg GF, Fouser LA, Artis D: Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011, 12 (5): 383-390. 10.1038/ni.2025.PubMedView ArticleGoogle Scholar
- Wan Q, Kozhaya L, ElHed A, Ramesh R, Carlson TJ, Djuretic IM, Sundrud MS, Unutmaz D: Cytokine signals through PI-3 kinase pathway modulate Th17 cytokine production by CCR6+ human memory T cells. J Exp Med. 2011, 208 (9): 1875-1887. 10.1084/jem.20102516.PubMedPubMed CentralView ArticleGoogle Scholar
- Mitra A, Raychaudhuri SK, Raychaudhuri SP: IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine. 2012, 60 (1): 38-42. 10.1016/j.cyto.2012.06.316.PubMedView ArticleGoogle Scholar
- Pan H, Hong F, Radaeva S, Gao B: Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol. 2004, 1 (1): 43-49.PubMedGoogle Scholar
- Zhuang Y, Peng LS, Zhao YL, Shi Y, Mao XH, Guo G, Chen W, Liu XF, Zhang JY, Liu T, Luo P, Yu PW, Zou QM: Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother. 2012, in pressGoogle Scholar
- Gessner MA, Werner JL, Lilly LM, Nelson MP, Metz AE, Dunaway CW, Chan YR, Ouyang W, Brown GD, Weaver CT, Steele C: Dectin-1-dependent interleukin-22 contributes to early innate lung defense against Aspergillus fumigatus. Infect Immun. 2012, 80 (1): 410-417. 10.1128/IAI.05939-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Chang H, Hanawa H, Liu H, Yoshida T, Hayashi M, Watanabe R, Abe S, Toba K, Yoshida K, Elnaggar R, Minagawa S, Okura Y, Kato K, Kodama M, Maruyama H, Miyazaki J, Aizawa Y: Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats. J Immunol. 2006, 177 (6): 3635-3643.PubMedView ArticleGoogle Scholar
- Savan R, McFarland AP, Reynolds DA, Feigenbaum L, Ramakrishnan K, Karwan M, Shirota H, Klinman DM, Dunleavy K, Pittaluga S, Anderson SK, Donnelly RP, Wilson WH, Young HA: A novel role for IL-22R1 as a driver of inflammation. Blood. 2011, 117 (2): 575-584. 10.1182/blood-2010-05-285908.PubMedPubMed CentralView ArticleGoogle Scholar
- BardJD GP, Anand M, Amin HM, Lai : Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia. 2008, 22 (8): 1595-1603. 10.1038/leu.2008.129.View ArticleGoogle Scholar
- Jin B, Wang RY, Qiu Q, Sugauchi F, Grandinetti T, Alter HJ, Shih JW: Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology. 2007, 122 (1): 15-27. 10.1111/j.1365-2567.2007.02607.x.PubMedPubMed CentralView ArticleGoogle Scholar
- Bogdan C: Nitric oxide and the immune response. Nat Immunol. 2001, 2 (10): 907-916. 10.1038/ni1001-907.PubMedView ArticleGoogle Scholar
- Missé D, Yssel H, Trabattoni D, Oblet C, Lo Caputo S, Mazzotta F, Pène J, Gonzalez JP, Clerici M, Veas F: IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol. 2007, 178 (1): 407-415.PubMedView ArticleGoogle Scholar
- Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices M, Gill D, Dunussi-Joannopoulos K, Collins M, Nickerson-Nutter C, Fouser LA, Young DA: IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008, 118 (2): 597-607.PubMedPubMed CentralGoogle Scholar
- Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld J-C, Dumoutier L: IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice. J Immunol. 2012, 188 (1): 462-469. 10.4049/jimmunol.1102224.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.